Replies to post #71486 on Biotech Values

[DewDiligence]

SGP – Asenapine approval sounds like a fait accompli inasmuch as the FDA does not put proposed labeling in a CRL if there are consequential issues outstanding.

http://finance.yahoo.com/news/US-FDA-Issues-Complete-prnews-14055997.html

The action letter includes proposed labeling for both indications and a request for supplemental data from the existing asenapine database.

This appears to be yet another licensing screw-up by PFE.